このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Innoviva マネジメント

マネジメント基準チェック /44

Innoviva'sの CEO はPavel Raifeldで、 May2020年に任命され、の在任期間は 4.08年です。の年間総報酬は$ 868.65Kで、 55.8%給与と44.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.019%を直接所有しており、その価値は$ 189.20K 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と6.3年です。

主要情報

Pavel Raifeld

最高経営責任者

US$868.6k

報酬総額

CEO給与比率	55.8%
CEO在任期間	4.1yrs
CEOの所有権	0.02%
経営陣の平均在職期間	4.1yrs
取締役会の平均在任期間	6.3yrs

経営陣の近況

Recent updates

Innoviva: Potentially Overvalued

Jun 21

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

CEO報酬分析

Innoviva の収益と比較して、Pavel Raifeld の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$181m
Dec 31 2023	US$869k	US$485k	US$180m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$233m
Mar 31 2023	n/a	n/a	US$233m
Dec 31 2022	US$2m	US$440k	US$214m
Sep 30 2022	n/a	n/a	US$293m
Jun 30 2022	n/a	n/a	US$99m
Mar 31 2022	n/a	n/a	US$188m
Dec 31 2021	US$1m	US$391k	US$266m
Sep 30 2021	n/a	n/a	US$309m
Jun 30 2021	n/a	n/a	US$265m
Mar 31 2021	n/a	n/a	US$253m
Dec 31 2020	US$2m	US$222k	US$224m

報酬と市場: Pavelの総報酬 ($USD 868.65K ) は、 US市場 ($USD 3.39M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Pavelの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Pavel Raifeld (40 yo)

4.1yrs

在職期間

US$868,648

報酬

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Pavel Raifeld	Chief Executive Officer	4.1yrs	US$868.65k	0.019% $ 191.3k
Stephen Basso	Chief Financial Officer	less than a year	US$1.18m	データなし
Marianne Zhen	Chief Accounting Officer & Secretary	5.9yrs	US$924.21k	0.075% $ 764.1k

4.1yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: INVAの経営陣は経験豊富であると考えられます ( 4.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jules Haimovitz	Independent Director	6.3yrs	US$446.02k	0.19% $ 1.9m
Sapna Srivastava	Independent Director	1.4yrs	US$547.11k	0.041% $ 417.5k
Derek Small	Independent Director	less than a year	データなし	データなし
Odysseas Kostas	Independent Director	6.5yrs	US$331.18k	0.17% $ 1.8m
Sarah Schlesinger	Independent Director	6.3yrs	US$367.25k	0.17% $ 1.7m
Mark DiPaolo	Independent Director	6.3yrs	US$396.59k	0.17% $ 1.7m

6.3yrs

平均在職期間

52.5yo

平均年齢

経験豊富なボード: INVAの取締役会は経験豊富であると考えられます ( 6.3年の平均在任期間)。

Innoviva マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Recent updates

New minor risk - Financial position

Innoviva: Potentially Overvalued

Now 21% undervalued

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Price target decreased by 23% to US$13.00

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 12% to US$15.17

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva Stock? Not Yet. Short Puts? Definitely.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Price target decreased to US$18.67

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Price target increased to US$20.50

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Innoviva Inc.: Short Puts Are Compelling

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Independent Chairman of the Board recently bought US$264k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva reports Q1 results

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

New 90-day high: US$12.51

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Investor sentiment improved over the past week

New 90-day high: US$11.81

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Innoviva: Only For Short-Term Traders

Third quarter earnings released

Innoviva reports Q3 results

New 90-day low: US$9.99

New 90-day low: US$10.85

New 90-day low - US$12.73

マネジメント基準チェック /44